A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs ASN 003 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Asana BioSciences
  • Most Recent Events

    • 25 Oct 2017 Results assessing safety and tolerability of ASN003 in patients with advanced solid tumors, were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
    • 25 Oct 2017 As of June 2017, nine eligible patients are enrolled in dose levels ranging from 10 - 240 mg QD, according to results presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
    • 24 Oct 2017 According to an Asana BioSciences media release, data from this trial will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top